• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Genetics Market
    Genetics News
    Genetics Stocks
    • Genetics Market
    • Genetics News
    • Genetics Stocks

    Genetic Technologies Limited Announces Research Collaboration with Two Medical Centers

    Jocelyn Aspa
    Feb. 01, 2019 09:05AM PST
    Genetics Investing

    Genetic Technologies (NASDAQ:GENE,ASX:GTG) has announced a research agreement between its subsidiary, Phenogen, Memorial Sloan Kettering Cancer Center, New York and the University of Cambridge. As quoted in the press release: This collaborative research study is to be led by Mark Robson, MD, Chief of the Breast Medicine Service at MSK. The study is to assess …

    Genetic Technologies (NASDAQ:GENE,ASX:GTG) has announced a research agreement between its subsidiary, Phenogen, Memorial Sloan Kettering Cancer Center, New York and the University of Cambridge.

    As quoted in the press release:

    This collaborative research study is to be led by Mark Robson, MD, Chief of the Breast Medicine Service at MSK. The study is to assess whether the provision of individual risk information informed by a polygenic risk score (PRS) reduces decisional conflict among BRCA mutation carriers considering preventive surgery.

    Executive Chairman of GTG, Dr Paul Kasian said, “the University of Cambridge has one of Europe’s leading academic departments of population health sciences and cancer genetic epidemiology. GTG is proud to be associated with these two prestigious research institutes for this project.

    This collaborative study provides two major benefits for GTG:

    (i) engagement and collaboration with high profile cancer genetics researchers in the U.S.A.  and Europe who are at the forefront of risk assessment research; and

    (ii) the resulting data has the potential to inform the design of future pipeline products for GTG

    The specific terms and conditions of the Agreement are confidential but at a high level, GTG will supply novel SNP-based genotyping for a clinical research study, through its CLIA laboratory facility, Phenogen Sciences Inc, on a fee for service basis.”

    Click here to read the full press release.

    asx:gtggenetic technologiesnasdaq:gene
    The Conversation (0)
    Go Deeper
    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Genetics Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×